OssiMend BA in Posterolateral Instrumented Lumbar Fusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-21

Study Completion Date

2027-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

NCT01494493

Degenerative Disc Disease

TERMINATED NA

OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion

NCT01873586

Degenerative Changes Stenosis Spondylosis

COMPLETED NA

Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine

NCT01968993

Degenerative Disc Disease Spinal Stenosis Spondylolisthesis

COMPLETED NA

A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System

NCT00678171

Degenerative Disc Disease

COMPLETED NA

OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study

NCT05405374

Lumbar Spine Disease Lumbar Spondylolisthesis Lumbar Spine Instability +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material. The primary endpoints are radiographic evidence of fusion and the absence of serious adverse events attributable to OssiMend Bioactive Moldable. The secondary objective is to evaluate the clinical outcomes over a period of 1 year (2 years, if possible).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Disease Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OssiMend™ Bioactive Moldable

Patients undergoing Lumber Spine Fusion

OssiMend™ Bioactive Moldable

Intervention Type DEVICE

Lumbar Spine fusion with OssiMend™ Bioactive Moldable

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OssiMend™ Bioactive Moldable

Lumbar Spine fusion with OssiMend™ Bioactive Moldable

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must be 18 years of age or older at the time of consent and must have a documented diagnosis of degenerative disc disease (DDD) that has failed to respond to nonoperative treatment for at least 6 months. DDD is defined by back and/or radicular pain with degeneration of the disc as confirmed by medical history, physical examination, and radiographic studies that may include CT, MRI, plain X-ray film, discography, myelography, etc. with one or more of the following findings:

* Instability as defined by \>3mm translation or \>5 degrees angulation
* Osteophyte formation of facet joints or vertebral endplates
* Decreased disc height, on average by \>2mm, but dependent upon the spinal level
* Herniated nucleus pulposus
* Facet joint degeneration/changes

Exclusion Criteria

1. Subject is under 18 years of age at the time of consent
2. Subject has had prior lumbar spine fusion surgery at any level
3. Subject is currently undergoing treatment for malignancy or has undergone treatment for malignancy
4. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
5. Subject has an active (local or systemic) infection or is undergoing adjunctive treatment for infection
6. Subjects under workers compensation or active litigation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No